WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report—download today for expert insights, data, and a clear view of the U.S. dredging market.→ Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

16.93 -0.73 (-4.13%)
Streaming Delayed Price Updated: 10:22 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioAge Labs, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across... 
Via MarketBeat
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗
Don't be too quick to jump on this biotech bandwagon. 
Via The Motley Fool
News headline image
BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗
BioAge Labs reported a mixed Q3 2025, beating revenue estimates by 94% with a narrower EPS loss. The clinical-stage biotech advanced its lead drug, BGE-102, with cash runway through 2029. 
Via Chartmill
News headline image
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development. 
Via The Motley Fool
News headline image
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗
This stock has caught fire after some recent events, but how long will that last? 
Via The Motley Fool
News headline image
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗
The clinical-stage biotech is working on a new type of weight management drug. 
Via The Motley Fool
News headline image
Here are the top movers in Thursday's session. ↗
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Gains 2%; BioAge Labs Shares Plunge ↗
 
Via Benzinga
News headline image
Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2% ↗
 
Via Benzinga
News headline image
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns ↗
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025. 
Via Benzinga
Topics Initial Public Offering
News headline image
Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Self-Driving Startup Pony.ai Files For U.S. IPO ↗
Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Prediction: These 2 Stocks Could Soar in 2025 ↗
The key word here is "could." 
Via The Motley Fool
News headline image
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom ↗
The future of the weight loss market might not revolve around GLP-1 drugs. 
Via The Motley Fool
News headline image
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock ↗
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now ↗
One of these businesses is a risky play, but the other is very likely to succeed. 
Via The Motley Fool
News headline image
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October ↗
There's a chance that its lead candidate could become one of the top drugs ever. 
Via The Motley Fool
News headline image
This IPO Biotech Stock Could Be the Next Eli Lilly ↗
BioAge has its eyes on a handful of truly gargantuan markets. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Obesity Drug Developer BioAge Makes Nasdaq Debut ↗
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials. 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.